Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease.

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-12-07 DOI:10.1080/14728222.2023.2274099

Jingqi Liu, Yang Song, Ye Wang, Huashan Hong

{"title":"Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease.","authors":"Jingqi Liu, Yang Song, Ye Wang, Huashan Hong","doi":"10.1080/14728222.2023.2274099","DOIUrl":null,"url":null,"abstract":"Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, but underlying mechanisms are not fully understood. In recent years, a growing body of evidence has emphasized the therapeutic role of vitamin D in NAFLD, but the specific mechanism remains to be investigated.Areas covered: This review summarized the roles of vitamin D/VDR (vitamin D receptor) pathway in different types of liver cells (such as hepatocytes, hepatic stellate cells, liver macrophages, T lymphocytes, and other hepatic immune cells) in case of NAFLD. Meanwhile, the effects of pathways in the gut-liver axis, adipose tissue-liver axis, and skeletal muscle-liver axis on the development of NAFLD were further reviewed. Relevant literature was searched on PubMed for the writing of this review.Expert opinion: The precise regulation of regional vitamin D/VDR signaling pathway based on cell-specific or tissue-specific function will help clarify the potential mechanism of vitamin D in NAFLD, which may provide new therapeutic targets to improve the safety and efficacy of vitamin D based drugs.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2023.2274099","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, but underlying mechanisms are not fully understood. In recent years, a growing body of evidence has emphasized the therapeutic role of vitamin D in NAFLD, but the specific mechanism remains to be investigated.

Areas covered: This review summarized the roles of vitamin D/VDR (vitamin D receptor) pathway in different types of liver cells (such as hepatocytes, hepatic stellate cells, liver macrophages, T lymphocytes, and other hepatic immune cells) in case of NAFLD. Meanwhile, the effects of pathways in the gut-liver axis, adipose tissue-liver axis, and skeletal muscle-liver axis on the development of NAFLD were further reviewed. Relevant literature was searched on PubMed for the writing of this review.

Expert opinion: The precise regulation of regional vitamin D/VDR signaling pathway based on cell-specific or tissue-specific function will help clarify the potential mechanism of vitamin D in NAFLD, which may provide new therapeutic targets to improve the safety and efficacy of vitamin D based drugs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非酒精性脂肪肝中的维生素D/维生素D受体途径。

引言：非酒精性脂肪肝（NAFLD）是世界范围内最常见的慢性肝病病因，但其潜在机制尚不完全清楚。近年来，越来越多的证据强调维生素D在NAFLD中的治疗作用，但具体机制仍有待研究。涵盖的领域：本文综述了维生素D/VDR（维生素D受体）途径在NAFLD病例中不同类型肝细胞（如肝细胞、肝星状细胞、肝巨噬细胞、T淋巴细胞和其他肝免疫细胞）中的作用。同时，进一步综述了肠肝轴、脂肪组织肝轴和骨骼肌肝轴通路对NAFLD发展的影响。在PubMed上搜索相关文献以撰写本综述。专家意见：基于细胞特异性或组织特异性功能对区域维生素D/VDR信号通路的精确调控将有助于阐明维生素D在NAFLD中的潜在机制，这可能为提高维生素D类药物的安全性和有效性提供新的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.